Article Text

Download PDFPDF
EP1266 Assessment of effectiveness of post-operative triptorelin administration in alleviating gastrointestinal symptoms in patients with deep infiltrating endometriosis in a multicentre, non-interventional study
  1. X Zhang1,
  2. V Perrot2 and
  3. H Li3
  1. 1Women’s Hospital School of Medicine, Zhejiang University, Hangzhou, China
  2. 2Ipsen Pharma, Boulogne-Billancourt, France
  3. 3Ipsen (Beijing) Pharmaceutical Science and Technology Development Co., Ltd, Beijing, China


Introduction/Background Adjuvant use of gonadotropin-releasing hormone agonists (e.g. triptorelin, Ipsen Pharma) can improve gastrointestinal (GI) symptoms in patients with deep infiltrating endometriosis (DIE) following conservative surgery. From a multicentre, non-interventional, observational study assessing the effectiveness of triptorelin in premenopausal Chinese patients with DIE (NCT01942369), this subgroup analysis evaluated the effectiveness of triptorelin in alleviating post-operative GI symptoms.

Methodology The study included premenopausal patients with DIE aged ≥18 years who underwent surgery 1 month before the study inclusion and received triptorelin intramuscular injections (3.75 mg every 28 days for up to 24 weeks). We assessed the intensity of GI symptoms using visual analogue scale (VAS) at pre-surgery and at 3, 6, 9, 12, 18- and 24-months post-surgery. The patients were categorized based on the number of triptorelin injections received (<3, 3–5 or >5 injections). Logistic regression was used to compare the improvement in GI symptoms across subgroups, and a P<0.05 was considered statistically significant.

Results Of 384 study patients, 119 (31%) women had GI symptoms, with 52, 32 and 35 patients reporting the intensity of GI symptoms as mild, moderate and severe, respectively, at the baseline. At 3 months, the proportion of women with GI symptoms decreased to 3% and remained low until the last follow-up (3% at 24 months) (table 1). At 24 months, the improvement in the intensity (a decrease of at least 3 points) was higher in patients receiving >5 injections (81%) or 3 to 5 injections (68%) in comparison with those receiving <3 injections (33%; with P values 0.006 and 0.060, respectively). Similar results were obtained at all-time points.

Conclusion This study confirmed the effectiveness of post-operative triptorelin therapy in alleviating GI symptoms in patients with DIE. The post-operative medical treatments for optimal outcomes need to be further addressed.

Disclosure This study was sponsored by Ipsen. The authors declare the following potential conflicts of interest with respects to the research, authorship and/or publication of this article: Valerie Perrot and Hongbo Li are employees of Ipsen. Xinmei Zhang has no conflict of interest to declare.

Abstract EP1266 Table 1

Proportion and intensity of gastrointestinal symptoms post triptorelin treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.